Group 1 PEGV | Group 2 PEGV?+?SSA | |
---|---|---|
Patients – n (%) | 35 (56.4) | 27 (43.6) |
Duration (mo.) of PEGV therapy – median (range) | 51 (15–72) | 30 (6–72)* |
Final weekly PEGV dose (mg) – median (range) | 105 (70–210) | 140 (70–280) |
Final daily PEGV dose (mg) | ||
10 mg – n (%) | 10 (28.6) | 11(40.7) |
15 mg – n (%) | 11 (31.4) | 2 (7.4) |
20 mg – n (%) | 9 (25.7) | 8 (29.6) |
25 mg – n (%) | 1 (2.8) | 1 (3.7) |
30 mg – n (%) | 4 (11.4) | 4 (14.8) |
40 mg – n (%) | 0 (0) | 1 (3.7) |
Group mean (±SD) | 16.8 (±6.3) | 17.9 (±8.4) |
Group median (range) | 15 (10–30) | 20 (10–40) |
Subgroup with IGF-I normalization at end of follow-up | 15 (10–30) | 10 (10–30) |
Subgroup with abnormal IGF-I levels at end of follow-up | 15 (10–20) | 20 (10–40)*# |
Pts. requiring dose reduction during follow-up a – n (%) | 5 (14.3) | 4 (14.8) |
Pts. with IGF-I normalization at any time during follow-up b – n (%) | 29 (82.8) | 18 (66.7) |
Pts. with IGF-I normalization at end of follow-up – n (%) | 28 (80) | 15 (55.5)* |
Final IGF-I levels | ||
μg/L,Median (range) | 212 (110–1216)# | 291 (150–1015)*# |
SDS (range) | 1.0 (−0.5–14.1)# | 1.9 (−0.4–9.8)*# |
μg/L,Mean (±SD) | 269 (± 203) | 372 (± 216)*# |
Significant growth of (residual) adenoma - n (%) | 0 (0) | 1 (3.7) |
Increase of liver enzymes - n (%) | 5 (14.3) | 3 (11.1) |
Injections site events - n (%) | 1 (2.9) | 1 (3.7) |